Mercy Hospital & Health Services Contact Us
MyChart
About Mercy
Join Our Team
set font size large set font size medium set font size small
email this page print this page
Novartis Cardiac Banner

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sponsored by Novartis
This study is currently recruiting participants.


Purpose

The purpose of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. 

ConditionInterventionPhase
AtherosclerosisDrug: Canakinumab
Drug: Placebo
Phase III

separator

Eligibility


Criteria
Inclusion Criteria:
  • Written informed consent
  • Male, or Female of non-child-bearing potential
  • Age ≥ 18 years.
  • Spontaneous MI at least 30 days before randomization.
  • hsCRP ≥ 2 mg/L
Exclusion Criteria:
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential
  • Any of the following concomitant diseases
  • Planned coronary revascularization (PCI or CABG)
  • Major non-cardiac surgical or endoscopic procedure within past 6 months
  • Multi-vessel CABG surgery within the past 3 years
  • Symptomatic patients with Class IV heart failure (HF) (New York Heart Association [NYHA].
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • History or evidence of active tuberculosis (TB) infection
Other protocol-defined inclusion/exclusion criteria may apply.

separator

Contacts and Locations


Physicians:
Ameer Kabour, MD
Raza Hashmi, MD
Tarif Kanaan, MD
Mohammad Alkhateeb, MD

Coordinators:
Coordinators:
Michelle Hickam, RN, BSN
Brenda Hoagland, RN, CCRC
Julie Neidhardt, RN, BSN

Please contact us at 419-251-4919 for further information about this study.
www.mercyweb.org
follow us online
facebook youtube


Contact us
Home  |  Sitemap

Disclaimer & Terms of Use  |  Privacy Statement  |  Notice of Privacy Practices
Copyright ©2013 Mercy. Last modified 10/24/2011